Gliptagreat M 1000 Tablet is a combination oral antidiabetic medication containing Metformin 1000 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin hormone levels, which stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner, further contributing to blood glucose regulation. The synergistic action of these agents helps achieve better glycemic control compared to monotherapy, reducing fasting and postprandial blood glucose levels. Gliptagreat M 1000 is typically prescribed as part of a comprehensive diabetes management plan, including diet and exercise, for patients inadequately controlled on metformin alone or those requiring combination therapy. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal impairment, or hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while rare but serious side effects include lactic acidosis and pancreatitis. Regular monitoring of renal function and glycemic parameters is recommended during therapy to ensure safety and efficacy.